Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

Netflix had won the streaming war long before investors noticed. I argue the same is already true in AI – and the winner is Alphabet. Everyone chases the “smartest chatbot,” but the real prize is who ...

Ohio State changed the tide of The Game and beat Michigan 27-9 to snap a four-game losing streak in the rivalry. With the return of wide receivers Carnell Tate and Jeremiah Smith from injury, Ohio ...

Between the two industry giants, Fidelity’s robust platform pulls slightly ahead Gordon Scott has been an active investor and technical analyst or 20+ years. He is a Chartered Market Technician (CMT).

Versus Systems Inc. provides a business-to-business software platform to drive user engagement through gamification and rewards. The company offers the eXtreme Engagement Online platform, which is ...

How to master the process that’s transforming management by Darrell Rigby, Jeff Sutherland and Hirotaka Takeuchi Agile innovation methods have revolutionized information technology. Over the past 25 ...